Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
$0.00
$0.00
$0.00
$0.00
N/A-2.3343 shs343 shs
EPRSQ
EPIRUS Biopharmaceuticals
$0.00
$0.00
$0.00
N/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
$5.47
$5.47
$5.47
$352.00
$127.45M2.46279 shsN/A
PZRXQ
PhaseRx
$0.00
$0.00
$0.00
N/A1.55N/AN/A
Spotlight Innovation Inc. stock logo
STLT
Spotlight Innovation
$0.00
$0.00
$0.04
N/AN/AN/A100 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
0.00%0.00%0.00%0.00%+∞
EPRSQ
EPIRUS Biopharmaceuticals
0.00%0.00%0.00%0.00%0.00%
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
0.00%0.00%0.00%0.00%0.00%
PZRXQ
PhaseRx
0.00%0.00%0.00%-50.00%-50.00%
Spotlight Innovation Inc. stock logo
STLT
Spotlight Innovation
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
EPRSQ
EPIRUS Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
PZRXQ
PhaseRx
N/AN/AN/AN/AN/AN/AN/AN/A
Spotlight Innovation Inc. stock logo
STLT
Spotlight Innovation
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
0.00
N/AN/AN/A
EPRSQ
EPIRUS Biopharmaceuticals
0.00
N/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
0.00
N/AN/AN/A
PZRXQ
PhaseRx
0.00
N/AN/AN/A
Spotlight Innovation Inc. stock logo
STLT
Spotlight Innovation
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
N/AN/AN/AN/AN/AN/A
EPRSQ
EPIRUS Biopharmaceuticals
N/AN/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
$36.55M3.49N/AN/A($67.63) per share-0.08
PZRXQ
PhaseRx
N/AN/AN/AN/AN/AN/A
Spotlight Innovation Inc. stock logo
STLT
Spotlight Innovation
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/A
EPRSQ
EPIRUS Biopharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
-$150.73MN/A0.00N/A-894.02%-3,350.55%-67.76%N/A
PZRXQ
PhaseRx
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Spotlight Innovation Inc. stock logo
STLT
Spotlight Innovation
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
N/AN/AN/AN/AN/A
EPRSQ
EPIRUS Biopharmaceuticals
N/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/AN/AN/AN/AN/A
PZRXQ
PhaseRx
N/AN/AN/AN/AN/A
Spotlight Innovation Inc. stock logo
STLT
Spotlight Innovation
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
N/AN/AN/A
EPRSQ
EPIRUS Biopharmaceuticals
N/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/A
0.95
0.71
PZRXQ
PhaseRx
N/AN/AN/A
Spotlight Innovation Inc. stock logo
STLT
Spotlight Innovation
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
200N/AN/ANot Optionable
EPRSQ
EPIRUS Biopharmaceuticals
70N/AN/ANot Optionable
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
5023.31 millionN/ANot Optionable
PZRXQ
PhaseRx
20N/AN/ANot Optionable
Spotlight Innovation Inc. stock logo
STLT
Spotlight Innovation
4N/AN/ANot Optionable

Recent News About These Companies

Outlook Business Spotlight Initiative - India's Best CEO
2025 Senior Spotlight: Newark Valley
Pokemon Go Spotlight Hour Schedule July 2025
KD Sunday Spotlight: Tunnels To Towers
Senior Spotlight: Sherburne-Earlville
Senior Spotlight: Charlotte Valley
FiSpo Spotlight: Pride All Year Long

Media Sentiment Over Time

Biostar Pharmaceuticals stock logo

Biostar Pharmaceuticals OTCMKTS:BSPM

$0.0001 0.00 (0.00%)
As of 07/1/2025 09:31 AM Eastern

Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides 12 other OTC products and 17 prescription-based pharmaceuticals. The company's OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. Its prescription pharmaceutical products include Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Danshen tablets; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. The company also operates a Website that serves as Internet-based China Hepatitis Internet hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through distributors and a network of sales people in approximately 28 provinces. The company was incorporated in 2007 and is headquartered in Xianyang, the People's Republic of China.

EPIRUS Biopharmaceuticals OTCMKTS:EPRSQ

EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.

ProMetic Life Sciences stock logo

ProMetic Life Sciences OTCMKTS:PFSCF

$5.47 0.00 (0.00%)
As of 11/18/2019

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

PhaseRx OTCMKTS:PZRXQ

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.

Spotlight Innovation stock logo

Spotlight Innovation OTCMKTS:STLT

Spotlight Innovation Inc., a pharmaceutical company, acquires and develops proprietary therapies to address unmet medical needs with an emphasis on rare, emerging, and neglected diseases. It identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations, and contract manufacturing organizations, as well as pursues product commercialization opportunities, including out-licensing and strategic partnerships. The company is developing Crotoxin, which is in Phase I clinical study for the treatment of cancer. It also develops various compounds for the treatment of viral infections, including Zika virus infection; and products derived from cobra venom to treat chronic pain. Spotlight Innovation Inc. has a license agreement with Indiana University Research and Technology Corporation to commercialize STL-182, an orally-available small molecule that might have therapeutic potential for treating spinal muscular atrophy. The company is based in Urbandale, Iowa.